Literature DB >> 888972

Relationship between colloid osmotic pressure and plasma protein concentration in the dog.

P D Navar, L G Navar.   

Abstract

This study was done to establish the correct relationship between protein concentration and plasma colloid osmotic pressure in the dog and to determine the possible influence of the relative albumin and globulin content (A:G ratio). Plasma samples from dogs, rats, and humans were evaluated for total protein concentration, globulin concentration, and colloid osmotic pressure. Samples were concentrated and diluted by ultrafiltration to provide a range of total protein concentrations from 1 to 12 g/dl. Rat and human plasma samples had A:G ratios of 1.4 and 2.1, respectively, and the relationship between protein concentration and colloid osmotic pressure was in agreement with the Landis-Pappenheimer equation. In contrast, dog plasma samples consistently exhibited lower colloid osmotic pressures for any given protein concentration. Two forms of empirical equations were derived to relate these parameters in the dog. Dog plasma samples had higher concentrations of globulin and the A:G ratio averaged 0.59 +/- 0.35 SD. There was a significant relationship between the A:G ratio and the plasma colloid osmotic pressure. Analysis of the possible effect of this altered relationship on glomerular filtration dynamics predicted that efferent plasma colloid osmotic pressure was not specifically affected and was dependent only on the filtration fraction and the plasma colloid osmotic pressure.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 888972     DOI: 10.1152/ajpheart.1977.233.2.H295

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  14 in total

Review 1.  Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems.

Authors:  Marilyn N Martinez
Journal:  AAPS J       Date:  2011-10-05       Impact factor: 4.009

Review 2.  Myocardial microvascular permeability, interstitial oedema, and compromised cardiac function.

Authors:  Ranjeet M Dongaonkar; Randolph H Stewart; Hans J Geissler; Glen A Laine
Journal:  Cardiovasc Res       Date:  2010-05-13       Impact factor: 10.787

3.  Renal failure associated with unrecognized hyperoncotic states after pediatric heart surgery.

Authors:  C Bartels; B Hadzik; M Abel; B Roth
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

4.  Interstitial distribution of charged macromolecules in the dog lung: a kinetic model.

Authors:  J C Parker; M Miniati; R Pitt; A E Taylor
Journal:  Ann Biomed Eng       Date:  1987       Impact factor: 3.934

5.  Autoregulation of superficial nephron function in the alloperfused dog kidney.

Authors:  J Heller; V Horácek
Journal:  Pflugers Arch       Date:  1979-10       Impact factor: 3.657

6.  Comparison of directly measured and calculated glomerular capillary pressure in the dog kidney at varying perfusion pressure.

Authors:  J Heller; V Horácek
Journal:  Pflugers Arch       Date:  1980-06       Impact factor: 3.657

7.  Hemodynamic pulmonary edema in dog lungs after contralateral pneumonectomy and mediastinal lymphatic interruption.

Authors:  A G Little; V K Langmuir; A H Singer; D B Skinner
Journal:  Lung       Date:  1984       Impact factor: 2.584

8.  Isoproternenol increases vascular volume expansion and urinary output after a large crystalloid bolus in healthy volunteers.

Authors:  Sven Asmussen; Michael Salter; Donald S Prough; George C Kramer; Christer Svensen; Melinda Sheffield-Moore; Michael P Kinsky
Journal:  Shock       Date:  2014-11       Impact factor: 3.454

9.  Transvascular fluid distribution of hyperoncotic Dextran solution.

Authors:  Kiyoshi Horiba; Yoshiaki Takumi; Mitiharu Kandori; Yasusuke Inoue; Hiroshi Noguchi
Journal:  J Anesth       Date:  1998-03       Impact factor: 2.078

10.  A possible role for leukotrienes in the regulation of glomerular haemodynamics in the dog.

Authors:  J Heller; V Horácek; S Kamarádová
Journal:  Pflugers Arch       Date:  1988-07       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.